Proactive Investors - Finance
10 Jan 2026, 12:01 UTC · 43w ago
Verdict
Headline takes no side. We score IMUX +0.90 across five claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
5 claims · scored −1 bearish … +1 bullish
Vidofludimus calcium demonstrated a 31% reduction in confirmed disability worsening in primary progressive MS patients in the phase 2 CALLIPER study.
More positive than 99% of claims this week
The CALLIPER study showed a 34% reduction in confirmed disability worsening in patients without baseline gadolinium lesions, suggesting a neuroprotective effect.
Continue reading
5 related stories
More positive than 98% of claims this week
Long-term EMPhASIS extension data showed 92.3% of relapsing-remitting MS patients remained free of 12-week confirmed disability worsening after 144 weeks, with only 13.8% of events independent of relapses.
More positive than 93% of claims this week
Immunic has strengthened its patent position, securing potential exclusivity for vidofludimus calcium to 2041 in key markets.
So whatExtending patent protection to 2041 substantially lengthens the commercial runway and enhances the net present value of the asset.
More positive than 85% of claims this week
Early findings for IMU-856 in celiac disease showed increases in natural GLP-1 levels, suggesting potential weight management benefits.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company reported positive Phase 2 clinical data showing a reduction in disability worsening for MS patients and strengthened its patent position.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
+25.0%
Price agrees with the score
$8.31 vs $6.65 close before publication (Jan 9) · not market-adjusted
IMUX chart →
